Hypoxia reduces CD138 expression and induces an immature and stem cell-like transcriptional program in myeloma cells

Differentiation induction enhances bortezomib efficacy and overcomes drug resistance in multiple myeloma

(2012) Jing-li Gu et al.   BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS

Clinical drug resistance linked to interconvertible phenotypic and functional states of tumor-propagating cells in multiple myeloma

(2012) A. Chaidos et al.   BLOOD

Hypoxia promotes dissemination of multiple myeloma through acquisition of epithelial to mesenchymal transition-like features

(2012) A. K. Azab et al.   BLOOD

Multiple myeloma cells expressing low levels of CD138 have an immature phenotype and reduced sensitivity to lenalidomide

(2012) YAWARA KAWANO et al.   INTERNATIONAL JOURNAL OF ONCOLOGY

CD138-negative clonogenic cells are plasma cells but not B cells in some multiple myeloma patients

(2012) N Hosen et al.   LEUKEMIA

Small molecule antibody targeting HLA class I inhibits myeloma cancer stem cells by repressing pluripotency-associated transcription factors

(2012) A Ikegame et al.   LEUKEMIA

Tumor-initiating capacity of CD138− and CD138+ tumor cells in the 5T33 multiple myeloma model

(2012) E Van Valckenborgh et al.   LEUKEMIA

Lenalidomide targets clonogenic side population in multiple myeloma: pathophysiologic and clinical implications

(2011) J. Jakubikova et al.   BLOOD

HIF Induces Human Embryonic Stem Cell Markers in Cancer Cells

(2011) J. Mathieu et al.   CANCER RESEARCH

Heparanase-enhanced shedding of syndecan-1 by myeloma cells promotes endothelial invasion and angiogenesis

(2010) A. Purushothaman et al.   BLOOD

Bone marrow stromal cell interaction reduces Syndecan-1 expression and induces kinomic changes in myeloma cells

(2010) Gwenny M. Fuhler et al.   EXPERIMENTAL CELL RESEARCH

Characterisation and relevance of CD138-negative plasma cells in plasma cell myeloma

(2010) S. REID et al.   International Journal of Laboratory Hematology

Retinoids regulate stem cell differentiation

(2010) Lorraine J. Gudas et al.   JOURNAL OF CELLULAR PHYSIOLOGY

Telomerase Inhibition Targets Clonogenic Multiple Myeloma Cells through Telomere Length-Dependent and Independent Mechanisms

(2010) Sarah K. Brennan et al.   PLoS One

Embryonic stem cell markers expression in cancers

(2009) Matthieu Schoenhals et al.   BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS

The Monoclonal Antibody nBT062 Conjugated to Cytotoxic Maytansinoids Has Selective Cytotoxicity Against CD138-Positive Multiple Myeloma Cells In vitro and In vivo

(2009) H. Ikeda et al.   CLINICAL CANCER RESEARCH

All-trans retinoic acid can intensify the growth inhibition and differentiation induction effect of rosiglitazone on multiple myeloma cells

(2009) Haiwen Huang et al.   EUROPEAN JOURNAL OF HAEMATOLOGY

Mesenchymal stromal cells revert multiple myeloma cells to less differentiated phenotype by the combined activities of adhesive interactions and interleukin-6

(2009) Nili Dezorella et al.   EXPERIMENTAL CELL RESEARCH

Sdc1 negatively modulates carcinoma cell motility and invasion

(2009) Tohru Ishikawa et al.   EXPERIMENTAL CELL RESEARCH

Hypoxia-inducible factor-2 is a novel regulator of aberrant CXCL12 expression in multiple myeloma plasma cells

(2009) S. K. Martin et al.   HAEMATOLOGICA

Suppression of Oct4 by Germ Cell Nuclear Factor Restricts Pluripotency and Promotes Neural Stem Cell Development in the Early Neural Lineage

(2009) W. Akamatsu et al.   JOURNAL OF NEUROSCIENCE

IRF4 addiction in multiple myeloma

(2008) Arthur L. Shaffer et al.   NATURE